- Sourcews Report
- File
- HTML
- Size
- 22 Ko
- URL response
- 100%
- Source quality
- 80%
- Sourcews Explorer
Crucell Announces STARŪ Research License Agreement with Celltrion, Inc
08.04.08 - 17:44 ... source : Crucell
... . Leiden, The Netherlands, 8 April 2008 - Dutch biotechnology company Crucell N.V. (Euronext, NASDAQ: CRXL, Swiss Exchange: CRX) today announced a non-exclusive STARŪ research license agreement with Celltrion, Inc. for the production of recombinant proteins. Under the agreement, Celltrion will evaluate Crucell's STARŪ technology for generating cell lines for the manufacture of biopharmaceuticals. Financial details of the agreement were not disclosed. About STARŪ Technology STARŪ technology is a production technology that is particularly useful for the production of recombinant human antibodies and proteins. It has a potentially broad application and is effective for production of antibodies and proteins on mammalian cell lines such as Crucell's PER.C6Ū human cell technology and the widely used Chinese hamster ovary (CHO) cell line. STARŪ technology contains genetic elements, called STARŪ elements, ...» Next (HTML)
